Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $1.442 million which missed the analyst consensus estimate of $2.057 million by 29.89 percent. This is a 33.55 percent decrease over sales of $2.170 million the same period last year.